唑来膦酸辅助治疗脊柱破骨细胞瘤的实验研究及临床应用

《唑来膦酸辅助治疗脊柱破骨细胞瘤的实验研究及临床应用》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、授予单位代码10089学号或申请号20150030中国图书分类号R738.1HebeiMedicalUniversity博士学位论文专业学位唑来膦酸辅助治疗脊柱破骨细胞瘤的实验研究及临床应用研究生：李鹏飞导师：赵宗茂教授专业：外科学二级学院：河北医科大学第二医院2018年4月目录中文摘要·········································································································5英文摘要···········································

2、·····························································11英文缩写········································································································20研究论文唑来膦酸辅助治疗脊柱破骨细胞瘤的实验研究及临床应用引言·····························································································

3、···········21第一部分唑来膦酸抑制体外培养破骨细胞功能的实验研究前言········································································································22材料与方法····························································································23结果··················································

4、······················································26附图········································································································28附表········································································································32讨论·······················

5、·················································································33小结········································································································37参考文献································································································37第二部分

6、关于唑来膦酸和伊班膦酸抑制破骨细胞特征比较的实验研究前言·······································································································46材料与方法···························································································47结果································································

7、·······································50附图·······································································································53讨论····································································